Skip to main content

Table 3 Comparison of characteristics of patients with uveitis

From: Epidemiology of pediatric uveitis and associated systemic diseases

Characteristics (1) Uveitis with Systemic immune-mediated disease, n = 44 (2) JIA-related uveitis, n = 23 (3) Idiopathic uveitis, n = 101 p-value
[(1) vs. (3)]
p-value
[(2) vs. (3)]
Sex, N(%)
 Male 25 (56.8) 15 (65.2) 48 (47.5) 0.303 0.126
 Female 19 (43.2) 8 (34.8) 53 (52.5)   
Median age at uveitis diagnosis, y (IQR) 13.0 (10.0–16.0) 11.0 (6.5–16.0) 13.0 (10.0–16.0) 0.914 0.251
Laboratory findings
 HLA-B27 tested, N 27 16 43   
 Positive, N (%) 8 (29.6) 7 (43.8) 5 (11.6) 0.059 0.006
 HLA-B51 tested, N 18 5 41   
 Positive, N (%) 5 (27.8) 1 (20.0) 7 (17.1) 0.347 0.871
 RF tested, N 41 23 71   
 Positive, N (%) 5 (12.2) 3 (13.0) 5 (7.0) 0.357 0.370
 ANA tested, N 40 23 66   
 Positive, N (%) 16 (40.0) 13 (56.5) 17 (25.8) 0.125 0.007
Type, N (%)
 Unilateral 18 (40.9) 15 (65.2) 54 (53.5) 0.164 0.306
 Bilateral 26 (59.1) 8 (34.8) 47 (46.5)   
Location, N (%)
 Anterior 22 (50.0) 13 (56.5) 52 (51.5) 0.633 0.779
 Intermediate 1 (2.3) 1 (4.4) 9 (8.9)   
 Posterior 1 (2.3) 0 (0.0) 2 (2.0)   
 Panuveitis 14 (31.8) 5 (21.7) 25 (24.8)   
 Unknown 6 (13.6) 4 (17.4) 13 (12.9)   
Treatment, N (%)
 Topical steroid 44 (100.0) 23 (100.0) 101 (100.0)   
 Systemic steroid 37 (84.1) 20 (87.0) 35 (34.6) < 0.001 < 0.001
 Synthetic DMARDs 31 (70.5) 17 (73.9) 15 (14.9) < 0.001 < 0.001
 Biological DMARDs 11 (25.0) 6 (26.1) 0 (0.0) < 0.001 < 0.001
Ocular complications, N (%) 21 (47.7) 11 (47.8) 35 (34.7) 0.137 0.238
  1. y years, JIA juvenile idiopathic arthritis, IQR interquartile range, HLA human leukocyte antigen, RF rheumatoid factor, ANA antinuclear antibody, DMARDs disease-modifying antirheumatic drugs